HopeS.RugoMD

Oncology • San Francisco, CA

Clinical Professor of Medicine, UCSF

Join to view full profile

Dr. Rugo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rugo's full profile

Already have an account?

Office
1600 Divisadero St
San Francisco, CA 94143
Phone+1 415-353-7070

Fax+1 415-353-7021

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1987 - 1990
University of California (San Francisco)Residency, Internal Medicine, 1984 - 1987
Perelman School of Medicine at the University of PennsylvaniaClass of 1984

Certifications & Licensure

CA State Medical License 1986 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Women's Health Castle Connolly, 2008
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer Start of enrollment: 2000 Dec 04
Completed
Phase 3
Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer Start of enrollment: 2001 Feb 01
Completed
Phase 1, Phase 2
Herbal Therapy in Treating Women With Metastatic Breast Cancer Start of enrollment: 2001 Aug 01
Completed
Phase 1, Phase 2
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer Start of enrollment: 2004 Nov 03
Completed
Phase 2
Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer Start of enrollment: 2004 May 01
Completed
Phase 2
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery Start of enrollment: 2004 Aug 01
Completed
Phase 2
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2006 Mar 01
Terminated
Phase 1, Phase 2
Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer Start of enrollment: 2007 Aug 20
Terminated
Phase 2
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer Start of enrollment: 2007 May 01
Completed
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow Start of enrollment: 2009 Feb 01
Terminated
Phase 2
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall Start of enrollment: 2013 Feb 01
Completed
Phase 1, Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib Start of enrollment: 2012 Apr 27
Completed
Phase 2
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Start of enrollment: 2012 May 01
Completed
Phase 1
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer Start of enrollment: 2012 Nov 01
Terminated
Phase 2
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Start of enrollment: 2012 Mar 27
Completed
Phase 1, Phase 2
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer Start of enrollment: 2012 Jul 12
Completed
Phase 1, Phase 2
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 2
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01
Terminated
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Start of enrollment: 2016 Nov 14
Active, not recruiting
Phase 1
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Start of enrollment: 2017 Sep 02
Active, not recruiting
Phase 2
Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer Start of enrollment: 2018 Jul 06
Completed
Phase 2
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC Start of enrollment: 2018 Dec 05
Recruiting
Phase 3
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Start of enrollment: 2018 Nov 28
Completed
Phase 2
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Start of enrollment: 2019 Jul 08
Recruiting
Phase 2
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial Start of enrollment: 2021 Nov 18
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care.
Heather N Moore, Marcus D Goncalves, Abigail M Johnston, Erica L Mayer, Hope S Rugo
Clinical Breast Cancer. 2025-01-01
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness.
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen
The Oncologist. 2024-12-06
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Hope S Rugo, Mike Campbell, Christina Yau, A Jo Chien, Anne M Wallace
Breast Cancer Research and Treatment. 2024-12-03

Journal Articles

Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study
M C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Amreen Husain, Sylvia Adams, Hope S Rugo, Carlos H Barrios, Eric P Winer, The New England Journal of Medicine
A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer Using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)
Hope S Rugo, Francisco Castillos, Beth Overmoyer, Mark J Ratain, Clinical Pharmacology & Therapeutics
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Hope S Rugo, Sara A Hurvitz, Lida A Mina, The New England Journal of Medicine
Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer
Benjamin L. Franc, Ben Marafino, Hope S. Rugo, David Seidenwurm, Journal of The National Comprehensive Cancer Network
Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Hope S Rugo, Bryan P Schneider, Alan Venook, Clinical Cancer Research
Join now to see all

Lectures

Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanc...
2019 ASCO Annual Meeting - 6/1/2019
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast ca...
2019 ASCO Annual Meeting - 6/1/2019
EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
The association of early toxicity and outcomes for patients treated with abemaciclib.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
The New World of Biosimilars in Oncology: Translation of Data to the Clinic
San Antonio Breast Cancer Symposium, 2013 International Symposium, San Antonio, Texas, USA
Join now to see all

Authored Content

Palbociclib plus Endocrine Therapy in Older Women with HR+/HER2– Advanced Breast Cancer: A Pooled Analysis of Randomised PALOMA Clinical StudiesAugust 2018

Press Mentions

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)November 26th, 2024
Challenging Case Conversation: A 45-Year-Old With Early-Stage Breast CancerSeptember 19th, 2024
Challenging Case Conversation: Metastasis in a Breast Cancer PatientSeptember 19th, 2024
Join now to see all